Evidence map›Paper›PMID 32977754›Full record

ArticleBMC cancer2020

A high neutrophil-to-lymphocyte ratio is a poor prognostic factor for castration-resistant prostate cancer patients who undergo abiraterone acetate or enzalutamide treatment.

Takashi Kawahara, Masashi Kato, Kenichi Tabata, Ippei Kojima, Hiroshi Yamada, Osamu Kamihira, Hideyasu Tsumura, Masatsugu Iwamura, Hiroji Uemura, Yasuhide Miyoshi

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC cancer, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed, 1 pooled it
1.6field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 1 synthesis or guideline pooled it, 16 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Inflammation and Myeloid Cells in Cancer Progression and Metastasis.Frontiers in cell and developmental biology · 2021
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Takashi KawaharaDepartments of Urology and Renal Transplantation, Yokohama City University Medical Center, Yokohama, 2320024, Japan. takashi_tk2001@yahoo.co.jp.ORCID http://orcid.org/0000-0002-7049-3379
Masashi KatoDepartment of Urology, Nagoya University, Nagoya, 4668560, Japan.
Kenichi TabataDepartment of Urology, Kitasato University School of Medicine, Sagamihara, 2520375, Japan.
Ippei KojimaDepartment of Urology, Nagoya University, Nagoya, 4668560, Japan.
Hiroshi YamadaDepartment of Urology, Nagoya University, Nagoya, 4668560, Japan.
Osamu KamihiraDepartment of Urology, Nagoya University, Nagoya, 4668560, Japan.
Hideyasu TsumuraDepartment of Urology, Kitasato University School of Medicine, Sagamihara, 2520375, Japan.
Masatsugu IwamuraDepartment of Urology, Kitasato University School of Medicine, Sagamihara, 2520375, Japan.
Hiroji UemuraDepartments of Urology and Renal Transplantation, Yokohama City University Medical Center, Yokohama, 2320024, Japan.
Yasuhide MiyoshiDepartments of Urology and Renal Transplantation, Yokohama City University Medical Center, Yokohama, 2320024, Japan.
Nagoya University · JPKitasato University · JPYokohama City University Medical Center · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundInflammatory cytokine markers, including the neutrophil-to-lymphocyte ratio (NLR), monocyte-lymphocyte ratio, and platelet-to-lymphocyte ratio, play important roles as prognostic markers in several solid malignancies, including prostate cancer. We previously reported the NLR as a poor prognostic marker in bladder cancer, upper-urothelial carcinoma, adrenocortical carcinoma, penile cancer, and prostate cancer. This study examined the importance of the NLR as a prognostic marker for castration-resistant prostate cancer (CRPC) patients who received abiraterone acetate or enzalutamide.

methodsA total of 805 prostate cancer patients developed in CRPC status were enrolled in this study. Of these patients, 449 received abiraterone acetate (ABI; 188 cases) or enzalutamide (ENZ; 261 cases) treatment, and the pre-treatment NLR values of these patients were obtained. We investigated the prognosis in those with higher and lower NLR values.

resultsThe median NLR was 2.90, and a receiver operating characteristics analysis suggested a candidate cut-off point of 3.02. The median overall survival (OS) was 17.3 months in the higher NLR group (≥3.02) and 27.3 months in the lower NLR group (< 3.02) (p < 0.0001). This trend was also observed in both the ABI and ENZ groups (ABI: 29.3 vs. 15.1 months; ENZ: NR vs. 19.5 months; p < 0.0001 and < 0.0001, respectively). A multivariate analysis revealed that a higher NLR was an independent risk factor. The NLR value was thus shown to be correlated with the prostate cancer progression.

conclusionsA higher NLR was associated with a poorer OS for CRPC patients who received ABI or ENZ. The NLR was positively correlated with prostate cancer progression.

Indexed as

Abiraterone AcetateAgedAntineoplastic Combined Chemotherapy ProtocolsBenzamidesHumansLymphocytesMaleNeutrophilsNitrilesPhenylthiohydantoinPrognosisProstatic Neoplasms, Castration-ResistantAbiraterone AcetateBenzamidesenzalutamideNitrilesPhenylthiohydantoinAbiraterone acetateEnzalutamideThe NLR

Identifiers

PMID32977754
PMCPMC7519532
OpenAlexW3088776773

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.